Articles

Friday Pearls

Friday Pearls

TOZAL Formulation Changes

Friday, June 12, 2009

It has come to our attention that the TOZAL formulation now being sold by AmeriSciences multi-level marketing company in Canada is different from the TOZAL formulation sold in the United States.

Foodies, Friends & Sustainable Fish

Friday, June 05, 2009

I gave a small mid-week dinner party for a group of nutrition-obsessed, molecular biologist/biochemist friends.  The evening was a huge success - food and otherwise.

Health Freedom Protection Act - H.R. 2117

Friday, May 29, 2009

Biosyntrx joins our manufacturing facility, Vitamin Research Products (VRP), in recommending that our Friday Pearl readers get involved to protect their health freedon.

EpiCor Receives New GRAS Designation.

Friday, May 29, 2009

A new safety and toxicology review by an independent panel of scientists shows that EpiCor is safe up to 3 grams per serving.

Free Radicals & Disease

Thursday, May 21, 2009

"All truth goes through three stages. First it is ridiculed. Then it is violently opposed. Finally, it is accepted as self-evident." Schopenhauer.   This week's Friday Pearl discusses the way free radicals and antioxidants interact with living organisms.

Omega-6 / Omega-3 Fatty Acid Team Work

Thursday, May 21, 2009

A study published in a peer-reviewed June 2009 biochemistry journal suggests that sincerely well-meaning Omega-3 fish oil sellers may be grossly over-simplifying essential fatty acid science when they suggest Omega-6 intake to be the Plague of the 21st Century.

How Much Fish Oil?

Friday, May 08, 2009

Fish Oil is the largest selling product in the supplement industry.  The American Heart Association clearly recommends physician care for those taking over 3 grams of Omega-3 EPA /DHA on a daily basis. 

Viruses and EpiCor

Friday, May 01, 2009

The gold standard for research in the dietary supplement industry is the human clinical trial, and several have now been completed on the immune system modulator, EpiCor.

Forcasting AMD Through 2050

Friday, April 17, 2009

The April issue of Archives of Ophthalmology published a simulation model of future age-related macular degeneration (AMD) designed to forecast the epidemiology of AMD in a variety of treatment scenarios up to the year 2050. 

A Biosyntrx Tribute to Michael Touch

Wednesday, March 11, 2009

Michael Touch, founder of Touch Scientific, died of heart failure at the young age of 64 on February 13, 2009. He is sorely missed by friends and family and an entire community of scientists and eye care professionals who depended on Mike for informative and engaging tear film chemistry discussions.

Pages:  1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48